Scimera BioScience Release: New Product Created in South Florida May Help Millions Who Suffer From G.I. Side Effects of Antibiotics
Published: Apr 03, 2013
MIAMI, FL--(Marketwired - April 03, 2013) -
ProPac, which uses the same complex blend of 11 probiotic strains and saccharomyces boulardii yeast found in Scimera's Asprega product, seeks to replace "good bacteria" that can be disturbed during antibiotic therapy. It is thought that this disturbance of gastrointestinal flora causes clinical symptoms of AAD.*
"We have seen significant evidence over the past half-dozen years that probiotics may reduce antibiotic-associated diarrhea for about 50 to 60% of patients who suffer from symptoms*," said South Florida physician Frederick Chaleff, M.D., founder and CEO of Scimera BioScience and one of the key players in formulating Asprega. "ProPac offers patients an opportunity to address the side effects caused by their antibiotics*+ -- and at a lower cost. ProPac costs less than half of full-size packages of competing probiotics."
At 20 billion CFUs (colony forming units), Asprega ProPac has more than double the potency of most probiotics. In addition, its delayed-release capsule delivers maximum effectivenesss in the digestive tract.
For information about Scimera BioScience and Asprega ProPac, visit www.scimera.com.
About Scimera BioScience
Scimera Bioscience® develops cutting-edge Bioceuticals that address cardiovascular, immune system, bone and joint, gastrointestinal, respiratory, prostate and a wide array of health issues. The Scimera team is comprised of Physicians, Pharmacists, Chemists, and Consumer Advocates with extensive clinical experience to produce science-based health solutions.
+These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
*Clinical research suggests use of probiotics may reduce onset of AAD. JAMA 2012, V307 #18
The Weinbach Group, Inc.